The store will not work correctly when cookies are disabled.
N-(5-bromo-6-methylpyrazin-2-yl)-3-nitrobenzamide
ID: ALA4090248
PubChem CID: 137643741
Max Phase: Preclinical
Molecular Formula: C12H9BrN4O3
Molecular Weight: 337.13
Molecule Type: Small molecule
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1nc(NC(=O)c2cccc([N+](=O)[O-])c2)cnc1Br
Standard InChI: InChI=1S/C12H9BrN4O3/c1-7-11(13)14-6-10(15-7)16-12(18)8-3-2-4-9(5-8)17(19)20/h2-6H,1H3,(H,15,16,18)
Standard InChI Key: MANMBAGJWLTSLR-UHFFFAOYSA-N
Molfile:
RDKit 2D
20 21 0 0 0 0 0 0 0 0999 V2000
22.0586 -1.8572 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.0575 -2.6768 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.7655 -3.0857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.4752 -2.6763 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.4724 -1.8536 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.7637 -1.4484 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.1835 -3.0838 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.1848 -3.9010 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
21.3494 -3.0848 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
20.6421 -2.6756 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
21.3488 -3.9020 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
24.8906 -2.6741 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
25.5989 -3.0815 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.5956 -3.8972 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.3031 -4.3046 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.0112 -3.8948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.0072 -3.0734 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2992 -2.6697 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.7129 -2.6612 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.7201 -4.3014 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
4 7 1 0
7 8 2 0
2 9 1 0
9 10 1 0
9 11 2 0
7 12 1 0
12 13 1 0
13 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 13 1 0
17 19 1 0
16 20 1 0
M CHG 2 9 1 10 -1
M END
Associated Targets(non-human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 337.13 | Molecular Weight (Monoisotopic): 335.9858 | AlogP: 2.71 | #Rotatable Bonds: 3 |
Polar Surface Area: 98.02 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 12.57 | CX Basic pKa: ┄ | CX LogP: 2.27 | CX LogD: 2.27 |
Aromatic Rings: 2 | Heavy Atoms: 20 | QED Weighted: 0.69 | Np Likeness Score: -1.87 |
References
1. Siddiqui-Jain A, Hoj JP, Hargiss JB, Hoj TH, Payne CJ, Ritchie CA, Herron SR, Quinn C, Schuler JT, Hansen MDH.. (2017) Pyridine-pyrimidine amides that prevent HGF-induced epithelial scattering by two distinct mechanisms., 27 (17): [PMID:28780159] [10.1016/j.bmcl.2017.07.063] |